Ortho Regenerative Technologies Inc. (OTCMKTS:ORTIF) Short Interest Update
Ortho Regenerative Technologies Inc. (OTCMKTS:ORTIF) Short Interest Update
Ortho Regenerative Technologies Inc. (OTCMKTS:ORTIF – Get Rating) saw a large drop in short interest in August. As of August 31st, there was short interest totalling 100 shares, a drop of 93.3% from the August 15th total of 1,500 shares. Based on an average daily volume of 0 shares, the short-interest ratio is presently ∞ days.
奧託再生科技股份有限公司(OTCMKTS：ORTIF-GET Rating)8月份空頭股數股價大幅下跌。截至8月31日，空頭股數共有100股，與8月15日的1500股相比，下降了93.3%。以日均成交量0股計算，目前短息比率為∞天。
Ortho Regenerative Technologies Price Performance
正射再生技術性價比
ORTIF stock remained flat at $0.20 during mid-day trading on Wednesday. The company has a market capitalization of $6.86 million, a P/E ratio of -1.78 and a beta of -1.16. The business has a fifty day simple moving average of $0.20 and a 200 day simple moving average of $0.19. Ortho Regenerative Technologies has a 12-month low of $0.13 and a 12-month high of $0.45.
在週三午盤交易中，ORTIF股價持平於0.20美元。該公司市值686萬美元，市盈率為-1.78，貝塔係數為-1.16。該業務的50日簡單移動均線切入位為0.20美元，200日簡單移動均線切入位為0.19美元。Ortho Regenerative Technologies的12個月低點為0.13美元，12個月高位為0.45美元。
Ortho Regenerative Technologies (OTCMKTS:ORTIF – Get Rating) last issued its earnings results on Thursday, June 23rd. The company reported ($0.02) earnings per share for the quarter. Analysts anticipate that Ortho Regenerative Technologies will post -0.08 earnings per share for the current fiscal year.
Ortho Regenerative Technologies(OTCMKTS：ORTIF-GET Rating)最近一次發佈收益報告是在6月23日(星期四)。該公司公佈了本季度每股收益(0.02美元)。分析師預計，Ortho Regenerative Technologies本財年的每股收益將為0.08美元。
Wall Street Analysts Forecast Growth
華爾街分析師預測經濟增長
Ortho Regenerative Technologies Company Profile
Ortho再生技術公司簡介
(Get Rating)
(獲取評級)
Ortho Regenerative Technologies Inc, an orthopaedic and sports medicine biologics company, engages in the research and development of novel therapeutic soft tissue repair technologies to enhance the success rate of sports medicine surgeries in Canada. It develops Ortho-R, a formulation for rotator cuff repair; Ortho-M, a biopolymer for meniscus repair; Ortho-C, a biopolymer for articular cartilage repair; and Ortho-V, a biopolymer for osteoarthritis healing, as well as ORTHO-T, a biopolymer formulation for tendon healing and regeneration.
Ortho Regenerative Technologies Inc是一家整形外科和運動醫學生物製劑公司，致力於研究和開發新型治療性軟組織修復技術，以提高加拿大運動醫學手術的成功率。它開發了用於肩袖修復的Ortho-R配方、用於半月板修復的生物聚合物Ortho-M、用於關節軟骨修復的生物聚合物Ortho-C、用於骨關節炎癒合的生物聚合物Ortho-V以及用於肌腱癒合和再生的生物聚合物配方Ortho-T。
Read More
閲讀更多內容
- Get a free copy of the StockNews.com research report on Ortho Regenerative Technologies (ORTIF)
- Is Lyft Going To Make It As Acquisition Rumors Swirl?
- Can Health Drink Maker Celsius Outrun Its Monster Rival?
- It's Time To Embrace Another 25% Decline In The S&P 500
- Four Cheap Stocks With Interesting Insider Activity
- These 3 Reports Will Tell Us Much About the Current Economy
- 免費獲取StockNews.com關於正畸再生技術的研究報告(ORTIF)
- 隨着收購傳言的甚囂塵上，Lyft能否成功？
- 健康飲料製造商Celsius能否超越其Monster競爭對手？
- 現在是時候接受標準普爾500指數再下跌25%的時候了
- 具有有趣內幕活動的四隻廉價股票
- 這三份報告將告訴我們許多關於當前經濟的情況。
Receive News & Ratings for Ortho Regenerative Technologies Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Ortho Regenerative Technologies and related companies with MarketBeat.com's FREE daily email newsletter.
接受《正畸再生技術日報》的新聞和評級-在下面輸入您的電子郵件地址，通過MarketBeat.com的免費每日電子郵件時事通訊接收對Ortho再生技術公司和相關公司的最新新聞和分析師評級的每日簡要摘要。
譯文內容由第三人軟體翻譯。